- Home
- PSO vs PCVX Comparison
PSO vs PCVX Comparison
Compare PSO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSO | PCVX |
|---|---|---|
| Founded | 1844 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 7.0B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSO | PCVX |
|---|---|---|
| Price | $15.72 | $57.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $88.25 |
| AVG Volume (30 Days) | 507.4K | ★ 1.1M |
| Earning Date | 02-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.26 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $14.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.02 | $31.51 |
| 52 Week High | $17.75 | $65.00 |
Technical Indicators
Market Signals| Indicator | PSO | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 42.58 |
| Support Level | $15.52 | $52.18 |
| Resistance Level | $17.70 | $58.77 |
| Average True Range (ATR) | 0.23 | 2.07 |
| MACD | -0.02 | -0.40 |
| Stochastic Oscillator | 17.80 | 9.25 |
Price Performance
Historical ComparisonAbout PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualifications, testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and the publishing house Penguin, and is now focused on serving as an educational resource and testing provider.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.